Tesla Loses Ground in Europe as BYD Accelerates EV Market Share in 2025 
Shell Plc Downgraded by RBC as Market Headwinds Pressure Valuation 
Microsoft Wins Approval to Build 15 New Data Centers in Wisconsin 
UK Politicians Call for Full Competition Review of Netflix’s Warner Bros Discovery Deal 
Baker Hughes Reports 11% Rise in Q4 Adjusted Profit Driven by LNG Demand 
Embraer Targets Growth as Regional Jet Demand Surges Post-Pandemic 
Trump Administration Takes Stake in USA Rare Earth to Boost U.S. Critical Minerals Supply 
BYD and Exxon Mobil Strengthen Hybrid Technology Partnership 
LVMH Succession Uncertainty Raises Governance Concerns Among Shareholders 
Airbus CEO Warns Staff to Prepare for Rising Geopolitical Risks Amid Trade Tensions 
Hermès Menswear Marks Historic Transition as Véronique Nichanian Bids Farewell in Paris 
Ford and GM Near Financing Deal to Support First Brands Group During Bankruptcy 
Hyundai Motor Shares Slide After Trump Signals Higher U.S. Tariffs on South Korean Goods 
ANTA Sports to Acquire Major Stake in Puma in €1.5 Billion Deal, Signaling Strategic Revival 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
WALTHAM, Mass., May 15, 2017 -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS), a fully integrated science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, announced that on May 15, 2017, the Company's Board of Directors granted Jose (Pepe) Carmona, the Company’s Chief Financial Officer, an option to purchase 125,000 shares of the Company's common stock with a per share exercise price of $34.96, the closing trading price of the Company’s common stock on the NASDAQ Global Market on the grant date of May 15, 2017. The option vests 25% on the first anniversary of the grant date, with the remaining 75% to vest in monthly installments over the three years thereafter, and has a ten-year term. The stock option was granted pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules for equity grants to induce Mr. Carmona to enter into employment with the Company.
About Radius
Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product, TYMLOS™ (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe. The Radius clinical pipeline includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug elacestrant (RAD1901) for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Radius' RAD140, a non-steroidal, selective androgen receptor modulator (SARM), is under investigation for potential use in hormone receptor positive breast cancer. For more information, please visit www.radiuspharm.com.
Investor Relations Contact: Barbara Ryan Email: [email protected] Phone: 203-274-2825 Media Contact: Lori Gorski Email: [email protected] Phone: 617-551-4096
